FAQ: Calidi Biotherapeutics Inc. Investor Webinar and Cancer Immunotherapy Pipeline

What is the main topic of the Calidi Biotherapeutics investor webinar?

The webinar will spotlight Calidi’s stem cell-based delivery platforms for oncolytic virus therapies, including updates on its FDA-cleared CLD-201 for solid tumors, CLD-400 for metastatic and lung cancer, and CLD-101 for high-grade gliomas.

When and where is the Calidi Biotherapeutics investor webinar taking place?

The live investor webinar is scheduled for April 24, 2025, at 4:15 p.m. ET. Details on how to access the webinar can be found in the full press release at https://ibn.fm/ppvW4.

Who will be featured in the Calidi Biotherapeutics investor webinar?

The event will feature Calidi’s new Chief Medical Officer, Dr. Guy Travis Clifton, who will discuss the company’s cancer immunotherapy pipeline and advancements.

What are Calidi Biotherapeutics’ stem cell-based platforms designed to do?

Calidi’s platforms utilize allogeneic stem cells to carry payloads of oncolytic viruses, designed to protect, amplify, and potentiate these viruses for enhanced efficacy and improved patient safety in treating various cancers.

What cancers are targeted by Calidi Biotherapeutics’ therapies?

Calidi’s therapies target high-grade gliomas, solid tumors, and metastatic and lung cancer, with programs like CLD-201, CLD-400, and CLD-101 advancing toward clinical trials.

How does Calidi Biotherapeutics’ approach differ from traditional cancer treatments?

Calidi’s approach uses stem cell-based delivery platforms and enveloped virotherapies to target and treat cancer more effectively, potentially preventing metastatic disease with enhanced efficacy and safety.

Where can I find more information about Calidi Biotherapeutics?

For more information, visit Calidi Biotherapeutics’ website at www.calidibio.com or view the full press release at https://ibn.fm/ppvW4.

What is the significance of Calidi Biotherapeutics’ FDA-cleared CLD-201?

CLD-201 represents a significant advancement in Calidi’s pipeline, being FDA-cleared and advancing toward clinical trials for the treatment of solid tumors, showcasing the potential of its stem cell-based delivery platform.